Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre,prospective,randomized,open-label,blinded-endpoint,controlled phase III non-inferiority trial protocol

Abstract

Rationale:

Alteplase is the only approved thrombolytic agent for acute stroke. An alternative plasminogen activator, tenecteplase, has been previously shown to increase early biological effectiveness (reperfusion) resulting in early clinical recovery in acute stroke patients with target mismatch on perfusion imaging; however, phase III data are lacking.

Aim and hypothesis:

In this study, we assess the efficacy and safety of tenecteplase compared to alteplase in acute stroke patients with target mismatch on perfusion imaging.

Methods and Design:

Tenecteplase (0.25 mg/kg) versus alteplase (0.9 mg/kg) for Stroke Thrombolysis Evaluation (TASTE) is a multicentre, prospective, randomized, open-label, blinded-endpoint (PROBE), controlled phase III non-inferiority trial (2 arms with 1:1 randomization) with an adaptive sample size re-estimation in patients with acute ischemic stroke meeting target mismatch criteria on perfusion imaging.

Sample size estimates:

Recruiting 728 patients (1:1 tenecteplase vs alteplase) would yield 90% power (two-sided alpha 0.05) to detect a treatment effect of 8% (26% modified Rankin scale (mRS) 0–1 in alteplase arm and 34% mRS 0–1 in tenecteplase arm), with an absolute non-inferiority margin of 3%. Following the pre-planned “promising zone” adaptive sample size re-estimation, the final sample size was set at 832 patients.

Study outcomes:

The primary outcome measure is the proportion of patients with an mRS score of 0–1 at 3 months. Secondary outcomes include the categorical shift in mRS at 3 months; the proportion of patients with: mRS 0–2, 5–6, and 6; reduction of the National Institutes of Health Stroke Scale (NIHSS) by 8 or more points or reaching 0–1 at 24 h; symptomatic intracerebral hemorrhage within 36 h; and death.

Discussion:

This pivotal trial will provide important data on the role of tenecteplase in acute ischemic stroke, and the use of imaging-based treatment decision-making for stroke thrombolysis.

Clinical trial protocol:

Trial Registration: ACTRN12613000243718, EudraCT 2015-002657-36

Keywords

Clinical trial stroke thrombolysis TASTE perfusion tenecteplase alteplase

Get full access to this article

View all access options for this article.

References

Bhatia

Hill

Shobha

, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke; 2010; 41: 2254–2258.

Van

Werf

Adgey

Ardissino

, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716–722.

Parsons

Spratt

Bivard

, et al. A randomized randomised trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366: 1099–1107.

Huang

Cheripelli

Lloyd

, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol 2015; 14: 368–376.

Bivard

Huang

McElduff

, et al. Impact of computed tomography perfusion imaging on the response to tenecteplase in ischemic stroke: analysis of 2 randomized controlled trials. Circulation 2017; 135: 440–448.

Logallo

Novotny

Assmus

, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol 2017; 16: 781–788.

Kvistad

Næss

Helleberg

, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol 2022; 21: 511–519.

Campbell

BCV

Mitchell

Churilov

, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 2018; 378: 1573–1582.

Campbell

BCV

Mitchell

Churilov

, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial. JAMA 2020; 323: 1257–1265.

10.

Menon

Buck

Singh

, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet 2022; 400: 161–169.

11.

Emberson

Lees

Lyden

, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929–1935.

12.

Mehta

Pocock

SJ.

Adaptive increase in sample size when interim results are promising: a practical guide with examples. Statistics in Medicine 2011; 30: 3267–3284.

13.

Kheiri

Osman

Abdalla

, et al. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J Thromb Thrombolysis 2018; 46: 440–450.

14.

Arora

Gaekwad

Evans

, et al. Diagnostic utility of computed tomography perfusion in the telestroke setting. Stroke; 2022; 53: 2917–2925.

15.

Mitchell

Yan

Churilov

, et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. Lancet 2022; 400: 116–125.